About: Efficacy and Safety of Recently Approved Drugs for Sickle Cell Disease: A Review of Clinical Trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and Safety of Recently Approved Drugs for Sickle Cell Disease: A Review of Clinical Trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Efficacy and Safety of Recently Approved Drugs for Sickle Cell Disease: A Review of Clinical Trials
Creator	Ali, Muhammad Anwar, Muhammad Ahmad, Asrar Aamir, Sobia Aiman, Wajeeha Ashar, Muhammad Chaudry, Hafsa Khan, Anam
source	Elsevier; Medline; PMC
abstract	Abstract Sickle cell disease is prevalent in several parts of the world. Most of the hospitalizations in these patients are related to pain crisis episodes. Moreover, the levels of hemoglobin are lower in sickle cell disease patients as compared to the general population. Complications related to sickle cell disease are managed with blood transfusions, hydroxyurea, and opioids. Despite these therapies, patients with sickle cell disease experience multiple pain crisis episodes leading to hospitalizations and end-organ damage. FDA has approved three new drugs, L-glutamine, voxelotor, and crizanlizumab, for the prophylaxis and treatment of complications related to sickle cell disease. This review aims to assess the efficacy and safety of recently approved drugs for the treatment of sickle cell disease. A comprehensive search was made on PubMed and clinicaltrials.gov to look for clinical trials reporting the efficacy and safety of recently approved drugs for sickle cell disease. Based on the results of clinical trials, L-glutamine, voxelotor and crizanlizumab were well tolerated by sickle cell disease patients. L-glutamine and crizanlizumab reduced the number of sickle cell crisis episodes, while voxelotor improved the level of hemoglobin in sickle cell disease patients. These drugs were effective alone and in combination with hydroxyurea.
has issue date	2020-08-22(xsd:dateTime)
bibo:doi	10.1016/j.exphem.2020.08.008
bibo:pmid	32841705
has license	els-covid
sha1sum (hex)	99fec8cfe5692e9b53fac4f8f8e656501ae7f588
schema:url	https://doi.org/10.1016/j.exphem.2020.08.008
resource representing a document's title	Efficacy and Safety of Recently Approved Drugs for Sickle Cell Disease: A Review of Clinical Trials
has PubMed Central identifier	PMC7442900
has PubMed identifier	32841705
schema:publication	Exp Hematol
resource representing a document's body	covid:99fec8cfe5692e9b53fac4f8f8e656501ae7f588#body_text
is schema:about of	named entity 'VOC' named entity 'Sickle Cell Disease' named entity 'Clinical Trials' named entity 'hemoglobin' named entity 'Clinical Trials' named entity 'L-glutamine' named entity 'phase II' named entity '8.5' named entity 'L-glutamine' named entity 'voxelotor' named entity 'FDA' named entity 'unconjugated bilirubin' named entity '10.8' named entity 'L-glutamine' named entity 'beta-globin' named entity 'redox potential' named entity 'reticulocyte count' named entity 'crizanlizumab' named entity 'statistically significant' named entity 'SCD' named entity 'hydroxyurea' named entity 'supportive therapy' named entity 'voxelotor' named entity 'phase III trial' named entity '3.2%' named entity 'gene expression' named entity 'clinical trials' named entity 'sickle' named entity 'sickle cell' named entity 'hydroxyurea' named entity 'phase III clinical trials' named entity 'hydroxyurea' named entity 'infarcts' named entity 'adhesion molecule' named entity 'voxelotor' named entity 'adverse effects' named entity 'solubility' named entity 'safety profile' named entity 'refractory' named entity 'L-glutamine' named entity 'nephropathy' named entity 'phase II trial' named entity 'L-glutamine' named entity 'epidemics' named entity 'quality of life' named entity 'mutation' named entity 'placebo' named entity 'adenine' named entity 'placebo' named entity 'vaso-occlusive crisis' named entity 'nucleotide' named entity 'fetal Hb' named entity 'statistically significant' named entity 'phase III trial' named entity 'hydroxyurea' named entity 'VOC' named entity 'L-glutamine' named entity 'treatment options' named entity 'L-glutamine' named entity 'toxicity' named entity 'crizanlizumab' named entity 'placebo' named entity 'adverse events' named entity 'gene' named entity 'RBCs' named entity 'sickle cell crisis' named entity 'adenine' named entity 'HbA' named entity 'crizanlizumab' named entity 'beta-globin' named entity 'gene expression' named entity 'randomized, double-blind' named entity 'clinical trials' named entity 'hydroxyurea'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software